JPWO2021207636A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021207636A5
JPWO2021207636A5 JP2022561477A JP2022561477A JPWO2021207636A5 JP WO2021207636 A5 JPWO2021207636 A5 JP WO2021207636A5 JP 2022561477 A JP2022561477 A JP 2022561477A JP 2022561477 A JP2022561477 A JP 2022561477A JP WO2021207636 A5 JPWO2021207636 A5 JP WO2021207636A5
Authority
JP
Japan
Prior art keywords
dnaj
sequence
seq
fusion protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520927A5 (https=
JP2023520927A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/026633 external-priority patent/WO2021207636A2/en
Publication of JP2023520927A publication Critical patent/JP2023520927A/ja
Publication of JPWO2021207636A5 publication Critical patent/JPWO2021207636A5/ja
Publication of JP2023520927A5 publication Critical patent/JP2023520927A5/ja
Pending legal-status Critical Current

Links

JP2022561477A 2020-04-10 2021-04-09 タンパク質凝集障害の処置のための組成物および方法 Pending JP2023520927A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063008251P 2020-04-10 2020-04-10
US63/008,251 2020-04-10
PCT/US2021/026633 WO2021207636A2 (en) 2020-04-10 2021-04-09 Compositions and methods for the treatment of protein aggregation disorders

Publications (3)

Publication Number Publication Date
JP2023520927A JP2023520927A (ja) 2023-05-22
JPWO2021207636A5 true JPWO2021207636A5 (https=) 2024-03-27
JP2023520927A5 JP2023520927A5 (https=) 2024-03-27

Family

ID=75747121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561477A Pending JP2023520927A (ja) 2020-04-10 2021-04-09 タンパク質凝集障害の処置のための組成物および方法

Country Status (10)

Country Link
US (1) US20230226223A1 (https=)
EP (1) EP4132955A2 (https=)
JP (1) JP2023520927A (https=)
KR (1) KR20220167324A (https=)
CN (1) CN115667289A (https=)
AU (1) AU2021254272A1 (https=)
BR (1) BR112022020444A2 (https=)
MX (1) MX2022012525A (https=)
TW (1) TW202204383A (https=)
WO (1) WO2021207636A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114057858B (zh) 2020-08-10 2023-03-21 上海瑞吉康生物医药有限公司 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽
US20240025954A1 (en) * 2020-10-26 2024-01-25 Sola Biosciences Llc Compositions and Methods for the Treatment of Alzheimer's Disease
EP4686478A1 (en) * 2024-07-31 2026-02-04 Consejo Superior de Investigaciones Científicas (CSIC) Qbp1 for use in the treatment and/or prevention of type 2 diabetes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1082413B1 (en) 1998-05-28 2008-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Aav5 vector and uses thereof
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
AU2002248297A1 (en) 2001-01-05 2002-07-16 Children's Hospital, Inc. Aav2 vectors and methods
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
JP2008125455A (ja) * 2006-11-22 2008-06-05 Sapporo Medical Univ ポリグルタミン凝集体形成阻害活性を有するポリペプチド
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
ES2683695T3 (es) 2010-01-12 2018-09-27 The University Of North Carolina At Chapel Hill Repeticiones terminales invertidas restrictivas para vectores virales
CA2788682C (en) 2010-02-05 2019-03-05 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules

Similar Documents

Publication Publication Date Title
JP7374119B2 (ja) 減少した肝臓向性を有するAAV9とAAVrh74とのハイブリッド組換えアデノ随伴ウイルス血清型
JP7801093B2 (ja) 細胞トランスフェクション及び/又はrAAVベクター産生の改善のための増強剤
ES2230569T3 (es) Funciones accesorias para uso en la produccion de viriones aav recombinantes.
JP2020522269A5 (https=)
Mori et al. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein
ES2703814T3 (es) Terapia génica para la enfermedad de Fabry
US7037713B2 (en) High-efficiency wild-type-free AAV helper functions
JP2021512649A5 (https=)
RU2017125234A (ru) Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
TW201629225A (zh) 第九因子基因療法
KR20160033217A (ko) 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
JPWO2020106916A5 (https=)
JP7616668B2 (ja) Ube3a遺伝子および発現カセットならびにそれらの使用
JP2017529395A5 (https=)
JP2024159800A (ja) 筋肉発現のためのハイブリッドプロモーター
JPWO2019153009A5 (https=)
JPWO2021207636A5 (https=)
JPWO2021222168A5 (https=)
US11780886B2 (en) Modified viral vectors and methods of making and using the same
JP2018536432A5 (https=)
US20210292373A1 (en) Aav vp1u chimeras
JPWO2021248038A5 (https=)
JPWO2021221995A5 (https=)
US10105450B2 (en) Promoter compositions
US20240425879A1 (en) Compositions and methods for adeno-associated (aav) virus dnase expression